Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Nov 5;2(11):e131. doi: 10.1038/mtna.2013.58

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 American Society of Gene & Cell Therapy

Molecular Therapy-Nucleic Acids is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

PMC Copyright notice

In vivo therapeutic efficacy. A single i.v. injection of the replication-deficient Ad5-AFP/NIS coated with PAMAM-G2-PEG-GE11 followed by a therapeutic dose of ¹³¹I (dc_300/GE11Ad5-AFP/NIS + ¹³¹I, radiotherapy) showed a significant delay in tumor growth and improved survival (a, b; ***P < 0.01) as compared with mice treated with saline only (NaCl-control, a, b). I.v. application of the oncolytic replication-selective Ad5-E1/AFP-E3/NIS with EGFR-targeted surface modification (dc_300/GE11Ad5-E1/AFP-E3/NIS, virotherapy) revealed a comparable delay in tumor growth and enhancement of survival (a, b). Combined radiovirotherapy treatment (dc_300/GE11Ad5-E1/AFP-E3/NIS + ¹³¹I, radiovirotherapy) resulted in a strongly enhanced therapeutic effect, as seen by significantly delayed tumor growth and further improved survival (a, b; ***P < 0.01). AFP, α-fetoprotein; EGFR, epidermal growth factor receptor; NIS, sodium iodide symporter.